JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma

Relapsed or Refractory B-cell Lymphoma Clinical Trial

Official title:
Early Exploratory Clinical Study of the Safety, Tolerability and Initial Efficacy of JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma

Status Recruiting

Clinical Trial Summary

Early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of relapsed or refractory B-cell lymphoma

Clinical Trial Description

This is a single-center, single-arm, open-treatment clinical study. In this study, approximately 10-20 adult and elderly patients with CD19-positive relapsed or refractory B-cell lymphoma will be enrolled for JY231 infusion therapy. The safety of JY231 was evaluated by observing adverse events after cell therapy. Evaluate the effectiveness of JY231 treatment compared to the results of the subjects' own previous standard treatment regimens or base data. Blood, bone marrow, and cerebrospinal fluid were collected before and 12 months after the JY231 infusion to detection. ;

Study Design

Related Conditions & MeSH terms

Lymphoma
Lymphoma, B-Cell
Relapsed or Refractory B-cell Lymphoma

Clinical Trial Details

NCT number	NCT06045585
Study type	Interventional
Source	Guangdong Second Provincial General Hospital
Contact	Qing Zhang, Doctoral
Phone	+86 20 8916 8162
Email	zhqing@vip.163.com
Status	Recruiting
Phase	Early Phase 1
Start date	August 18, 2023
Completion date	December 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04056975` - Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma	Phase 1
Not yet recruiting	`NCT06062641` - Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL	Phase 2
Recruiting	`NCT05806580` - Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma	Phase 4
Recruiting	`NCT03208556` - Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma	Phase 1
Not yet recruiting	`NCT05814848` - A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma	Phase 4
Recruiting	`NCT03391726` - CART-19 Cells for R/R B-cell Lymphoma	Phase 2/Phase 3
Recruiting	`NCT04887025` - Exploratory Study of a Novel Oncolytic Vaccinia Virus RGV004 in the Treatment of Refractory/Relapsed B-cell Lymphoma	Phase 1
Recruiting	`NCT05720052` - A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma	Phase 1/Phase 2